858 Therapeutics
Umi Chong has worked in the finance and accounting industry since 2000. Umi began their career at Syrrx, Inc. as the Controller, where they worked until 2005. Umi then joined Takeda San Diego as the Sr. Director of Finance & Site Controller, where they worked until 2022. Umi is currently employed at 858 Therapeutics as the Sr. Director of Finance and Controller.
Umi Chong attended Indiana University Bloomington.
This person is not in any offices
858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.